Joseph Piscitelli
Overview
Explore the profile of Joseph Piscitelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
13
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Elmeliegy M, Viqueira A, Vandendries E, Hickman A, Conte U, Irby D, et al.
Target Oncol
. 2025 Feb;
PMID: 40000533
Background: Elranatamab is a BCMA-CD3 bispecific antibody approved for the treatment of relapsed or refractory multiple myeloma. Cytokine release syndrome is one of the most common adverse events associated with...
2.
Piscitelli J, Reddy M, Wollenberg L, Del Frari L, Gong J, Matschke K, et al.
Cancer Chemother Pharmacol
. 2024 Jun;
94(3):337-347.
PMID: 38878209
Background: A clinical drug-drug interaction (DDI) study was designed to evaluate the effect of multiple doses of modafinil, a moderate CYP3A4 inducer at a 400 mg QD dose, on the...
3.
Piscitelli J, Reddy M, Wollenberg L, Del Frari L, Gong J, Wood L, et al.
Clin Pharmacokinet
. 2024 Feb;
63(4):483-496.
PMID: 38424308
Background And Objectives: Encorafenib is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma or metastatic colorectal cancer, respectively, with selected BRAF V600 mutations. A...
4.
Liyanage M, Blaquera C, Piscitelli J, Penzak S, Nolin T, Paine M, et al.
Int J Clin Pharmacol Ther
. 2023 Apr;
61(6):262-269.
PMID: 37042268
Objective: Fexofenadine is a probe drug used to phenotype P-glycoprotein (P-gp) and organic anion transporting polypeptide (OATP) 1B1/3 activities. This study evaluated a limited sampling strategy using plasma concentrations and/or...
5.
Piscitelli J, Hens B, Tomaszewska I, Wollenberg L, Litwiler K, McAllister M, et al.
Mol Pharm
. 2023 Apr;
20(5):2589-2599.
PMID: 37037186
Encorafenib is a kinase inhibitor indicated for the treatment of patients with BRAF mutant melanoma and BRAF mutant metastatic colorectal cancer. To understand the effect of food and coadministration with...
6.
Piscitelli J, Nikanjam M, Capparelli E, Blaquera C, Penzak S, Nolin T, et al.
Ther Drug Monit
. 2023 Jan;
45(4):539-545.
PMID: 36645711
Background: Fexofenadine is a recommended in vivo probe drug for phenotyping P-glycoprotein (P-gp) and organic anion transporting polypeptide (OATP) 1B1/3 transporter activities. This study evaluated a limited sampling strategy using...
7.
Luterbach C, Qiu H, Hanafin P, Sharma R, Piscitelli J, Lin F, et al.
Antimicrob Agents Chemother
. 2022 Sep;
66(10):e0059122.
PMID: 36125299
Antimicrobial resistance is a global threat. As "proof-of-concept," we employed a system-based approach to identify patient, bacterial, and drug variables contributing to mortality in patients with carbapenem-resistant Klebsiella pneumoniae (CR)...
8.
Piscitelli J, Chen J, LaBadie R, Salageanu J, Chung C, Tan W
Clin Drug Investig
. 2022 Feb;
42(3):221-235.
PMID: 35195881
Background And Objective: Dacomitinib is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations. To...
9.
Piscitelli J, Nikanjam M, Best B, Acosta E, Mirochnick M, Clarke D, et al.
J Acquir Immune Defic Syndr
. 2021 Oct;
89(1):108-114.
PMID: 34629412
Background: A knowledge gap exists for dolutegravir (DTG) pharmacokinetics and safety during the first 4 weeks of life, preventing safe and effective DTG use in neonates. Setting: Population pharmacokinetic modeling...
10.
Mehta R, Piscitelli J, Wolstenholme A, Fu C, Crauwels H, Wynne B, et al.
Clin Pharmacol
. 2020 Jul;
12:49-52.
PMID: 32607002
Dolutegravir 50 mg (DTG) and rilpivirine 25 mg (RPV) are a newly approved 2-drug regimen for the treatment of HIV in virally suppressed patients. A 2-part study evaluated the relative...